Brian Jonas, MD; PhD

Assistant Professor

  • 381 Citations
  • 8 h-Index
20042019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Brian Jonas is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 7 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Co-Repressor Proteins Medicine & Life Sciences
decitabine Medicine & Life Sciences
Azacitidine Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Nuclear Receptor Co-Repressor 2 Medicine & Life Sciences
Hematopoietic Stem Cells Medicine & Life Sciences
Alternative Splicing Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2004 2019

  • 381 Citations
  • 8 h-Index
  • 25 Article
  • 5 Review article
  • 3 Comment/debate
  • 1 Letter
1 Citation (Scopus)
Multiple Myeloma
Hematopoietic Stem Cells
Cell Survival
Stem Cells
Transplants
Open Access
Azacitidine
Cytarabine
Acute Myeloid Leukemia
Safety
Asthenia

Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia

Lin, T-Y., Zhu, Y., Li, Y., Zhang, H., Ma, A. H., Long, Q., Keck, J., Lam, K., Pan, C-X. & Jonas, B., Aug 1 2019, In : Nanomedicine: Nanotechnology, Biology, and Medicine. 20, 102004.

Research output: Contribution to journalArticle

Daunorubicin
Stem cells
Acute Myeloid Leukemia
Micelles
Leukemia

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia

Medeiros, B. C., Chan, S. M., Daver, N. G., Jonas, B. & Pollyea, D. A., Jan 1 2019, In : American Journal of Hematology.

Research output: Contribution to journalReview article

Open Access
Acute Myeloid Leukemia
Survival
Recurrence
Physiologic Monitoring
Therapeutics
1 Citation (Scopus)

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Cortes, J. E., Khaled, S., Martinelli, G., Perl, A. E., Ganguly, S., Russell, N., Krämer, A., Dombret, H., Hogge, D., Jonas, B., Leung, A. Y. H., Mehta, P., Montesinos, P., Radsak, M., Sica, S., Arunachalam, M., Holmes, M., Kobayashi, K., Namuyinga, R., Ge, N. & 3 others, Yver, A., Zhang, Y. & Levis, M. J., Jul 1 2019, In : The Lancet Oncology. 20, 7, p. 984-997 14 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Drug Therapy
Cytarabine
Intravenous Infusions
Survival